2-Bromo-1-(3-methoxyphenyl)ethanone
2-Bromo-1-(3-methoxyphenyl)ethanone structure
|
Common Name | 2-Bromo-1-(3-methoxyphenyl)ethanone | ||
|---|---|---|---|---|
| CAS Number | 5000-65-7 | Molecular Weight | 229.071 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 278.1±15.0 °C at 760 mmHg | |
| Molecular Formula | C9H9BrO2 | Melting Point | 60-62 °C(lit.) | |
| MSDS | Chinese USA | Flash Point | 122.0±20.4 °C | |
| Symbol |
GHS05, GHS07 |
Signal Word | Danger | |
|
The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
J. Clin. Pharmacol. 54(8) , 874-80, (2014) An extensive investigation on pharmacokinetics of clopidogrel and its metabolites as well as pharmacodynamics of the drug was performed in patients with cardiovascular disease carrying various alleles coding CYP2C19 isoenzyme. The influence of non-genetic fac... |
|
|
Identification of alcohol-dependent clopidogrel metabolites using conventional liquid chromatography/triple quadrupole mass spectrometry.
Rapid Commun. Mass Spectrom. 28(11) , 1285-92, (2014) Clopidogrel (CLO) is a prodrug used to prevent ischemic events in patients undergoing percutaneous coronary intervention or with myocardial infarction. A previous study found ethyl clopidogrel (ECLO) is formed by transesterification of CLO when incubated with... |
|
|
CYP-independent inhibition of platelet aggregation in rabbits by a mixed disulfide conjugate of clopidogrel.
Thromb. Haemost. 112(6) , 1304-11, (2014) Dual antiplatelet therapy with clopidogrel and aspirin has been the standard of care in the United States for patients with acute coronary syndromes (ACS) and/or undergoing percutaneous coronary interventions (PCI). However, the effectiveness of clopidogrel v... |
|
|
Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study.
Clin. Pharmacol. Ther. 96(6) , 713-22, (2014) Clopidogrel is an oral antiplatelet prodrug, the majority of which is hydrolyzed to an inactive metabolite by hepatic carboxylesterase 1 (CES1). Most angiotensin-converting enzyme inhibitors (ACEIs) are also metabolized by this enzyme. We examined the effects... |
|
|
Hepatic microsomal thiol methyltransferase is involved in stereoselective methylation of pharmacologically active metabolite of prasugrel.
Drug Metab. Dispos. 42(7) , 1138-45, (2014) Prasugrel, a thienopyridine antiplatelet drug, is converted in animals and humans to the pharmacologically active metabolite R-138727 [(2Z)-{1-[(1RS)-2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4-sulfanylpiperidin-3-ylidene}ethanoic acid], which has two chir... |
|
|
Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS.
J. Pharm. Biomed. Anal. 48(4) , 1219-24, (2008) A quantitative method for the determination of clopidogrel active metabolite (AM) in human plasma was developed and validated using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Clopidogrel AM contains a thiol group, thus requiring stabilization ... |
|
|
Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry.
Rapid Commun. Mass Spectrom. 21(2) , 169-79, (2007) Two fast and sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS)-based bioanalytical assays were developed and validated to quantify the active and three inactive metabolites of prasugrel. Prasugrel is a novel thienopyridine prodrug that is me... |